The safety and efficacy of repeated courses of tissue-type plasminogen activator in patients with stuck mitral valves who did not fully respond to the initial thrombolytic course

被引:5
作者
Shapira, Y
Vaturi, M
Hasdai, D
Battler, A
Sagie, A
机构
[1] Tel Aviv Univ, Sackler Sch Med, Valvular Clin, Dept Cardiol, IL-69978 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dan Sheingarten Ecocaridog Unit, Dept Cardiol, IL-69978 Petah Tiqwa, Israel
关键词
prosthetic valve thrombosis; tissue-type plasminogen activator;
D O I
10.1046/j.1538-7836.2003.00117.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In carefully selected patients with stuck mitral valves, thrombolytic therapy is becoming an established therapeutic modality. However, the management of patient with a suboptimal response to an initial thrombolytic course is unclear. The objective was to evaluate the efficacy and safety of readministration of tissue-type plasminogen activator (rt-PA) in patients with stuck mitral valves in whom the first thrombolytic course has failed to restore normal prosthetic valve function. The study group included patients who received rt-PA and did achieve a full restoration of valve function after the initial Course. Data were gathered on the safety and Success rates of additional thrombolytic courses in the same hospitalization period, and their predictors. Twelve patients with stuck mitral valves experienced a total of 13 episodes in which a full resolution of leaflet abnormality was not achieved after the initial thrombolytic course. A repeated thrombolytic course was attempted in 10 patients (11 episodes). Six patients (60%) showed full success rate with repeated thrombolysis, one (10%) showed partial success, and three patients (30%) had no improvement following the second course. These last three were those with initial failure. Age. gender, valve model, worst functional class. time since valve implantation and International Normalized Ratio (INR) levels were similar in both groups. No major adverse events were noted. In this small group of patients with stuck mitral valves, readministration of rt-PA after a partial response to an initial thrombolytic course was effective and safe. However, total failure of the first thrombolytic course predicted inefficiency of further courses.
引用
收藏
页码:725 / 728
页数:4
相关论文
共 21 条
[1]   RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR PROSTHETIC MITRAL-VALVE THROMBOSIS [J].
ASTENGO, D ;
BADANO, L ;
BERTOLI, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (04) :259-259
[2]  
Barbash GI, 2001, CIRCULATION, V103, P954
[3]   REPEAT INFUSIONS OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION AND EARLY RECURRENT MYOCARDIAL-ISCHEMIA [J].
BARBASH, GI ;
HOD, H ;
ROTH, A ;
FAIBEL, HE ;
MANDEL, Y ;
MILLER, HI ;
RATH, S ;
ZAHAV, YH ;
RABINOWITZ, B ;
SELIGSOHN, U ;
PELLED, B ;
SCHLESINGER, Z ;
MOTRO, M ;
LANIADO, S ;
KAPLINSKY, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 16 (04) :779-783
[4]   Guidelines for the management of patients with valvular heart disease - Executive summary - A report of the American College of Cardiology American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease) [J].
Bonow, RO ;
Carabello, B ;
de Leon, AC ;
Edmunds, LH ;
Fedderly, BJ ;
Freed, MD ;
Gaasch, WH ;
McKay, CR ;
Nishimura, RA ;
O'Gara, PT ;
O'Rourke, RA ;
Rahimtoola, SH ;
Ritchie, JL ;
Cheitlin, MD ;
Eagle, KA ;
Gardner, TJ ;
Garson, A ;
Gibbons, RJ ;
Russell, RO ;
Ryan, TJ ;
Smith, SC .
CIRCULATION, 1998, 98 (18) :1949-1984
[5]   ACC/AHA guidelines for the management of patients with valvular heart disease - A report of the American College of Cardiology American Heart Association Task Force on practice guidelines (Committee on Management of Patients with Valvular Heart Disease) [J].
Bonow, RO ;
Carabello, B ;
De Leon, AC ;
Edmunds, LH ;
Fedderly, BJ ;
Freed, MD ;
Gaasch, WH ;
Mckay, CR ;
Nishimura, RA ;
O'Gara, PT ;
O'Rourke, RA ;
Rahimtoola, SH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (05) :1486-1582
[6]   TREATMENT OF PROSTHETIC TRICUSPID-VALVE THROMBOSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
CAMBIER, P ;
MOMBAERTS, P ;
DEGEEST, H ;
COLLEN, D ;
VANDEWERF, F .
EUROPEAN HEART JOURNAL, 1987, 8 (08) :906-909
[7]  
HERRING D, 2001, EUR HEARTJ SQ, pQ22
[8]   EMERGENCY CORONARY-ARTERY BYPASS-SURGERY PRESERVES GLOBAL AND REGIONAL LEFT-VENTRICULAR FUNCTION AFTER INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR THERAPY FOR ACUTE MYOCARDIAL-INFARCTION [J].
KEREIAKES, DJ ;
TOPOL, EJ ;
GEORGE, BS ;
ABBOTTSMITH, CW ;
STACK, RS ;
CANDELA, RJ ;
ONEILL, WW ;
MARTIN, LH ;
CALIFF, RM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (05) :899-907
[9]   Guidelines for management of left-sided prosthetic valve thrombosis: A role for thrombolytic therapy [J].
Lengyel, M ;
Fuster, V ;
Keltai, M ;
Roudaut, R ;
Schulte, HD ;
Seward, JB ;
Chesebro, JH ;
Turpie, AGG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (06) :1521-1526
[10]   Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis [J].
Manteiga, R ;
Souto, JC ;
Altès, A ;
Mateo, J ;
Arís, A ;
Dominguez, JM ;
Borrás, X ;
Carreras, F ;
Fontcuberta, J .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1998, 115 (04) :780-784